Your session is about to expire
← Back to Search
Ramucirumab + Somatostatin Analog for Carcinoid Tumor
Study Summary
This trial is testing a drug to see if it can treat advanced, progressive carcinoid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 3 trial • 1253 Patients • NCT01168973Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your liver enzyme levels are not too high, unless you have cancer that has spread to your liver.My cancer has worsened in the last year, shown by scans.I can carry out all my usual activities without help.My cancer cannot be removed by surgery and has spread.I have painful gallstones.I agree to use birth control during and up to 4 months after the study.The amount of protein in your urine must be very low, and if it's a little high, a 24-hour urine test must show that it's still within a certain limit.I have not had severe gastrointestinal bleeding in the last 3 months.I have had a serious blood clot in the last 3 months.I haven't had a heart attack or stroke in the last 6 months.My high blood pressure is not well controlled despite taking medication.I haven't had serious heart issues like heart failure or irregular heartbeats in the last 6 months.My blood, liver, kidney, and coagulation tests are within normal ranges.My blood clotting levels are within normal range, and if on blood thinners, my dose has been stable for at least 14 days.I do not have severe health issues that could interfere with the study.I have a major surgery planned during the trial.I have no cancer history except for certain skin cancers or cancers I've been free of for 5 years.I haven't had chemotherapy or radiotherapy in the last 4 weeks and have recovered from any side effects.I have a tumor that can be measured with scans or exams.I am not pregnant or breastfeeding.I have not had major surgery in the last 28 days or a device placement in the last 7 days.I am 18 years old or older.I haven't had any serious wounds, ulcers, or bone fractures in the last 28 days.I do not have uncontrolled brain or spinal cord cancer that needs steroids.I am on daily aspirin or similar blood thinners, but no more than 325 mg/day.I have a confirmed low- to intermediate-grade neuroendocrine tumor, but not in the pancreas.I have severe liver disease, with complications like confusion or fluid in my abdomen.My cancer has worsened in the last year, as shown by scans.Your creatinine levels are within a certain range.I have a confirmed low- to intermediate-grade neuroendocrine tumor, but not in the pancreas.
- Group 1: Ramucirumab In Combination With Somatostatin Analog
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there a high risk associated with Ramucirumab?
"Ramucirumab has been evaluated in a Phase 2 trial, so while there is some evidence to support its safety, more research needs to be done to confirm its efficacy."
What is the primary illness that Ramucirumab has been shown to target?
"Ramucirumab is a medication that, while typically used to treat advanced directives, can also be effective for biliary fistula, vasoactive intestinal peptide tumors, and octreotide."
How many people are allowed to be a part of this clinical trial at one time?
"This study has completed recruitment for participants. The trial was first posted on 6/14/2016, with the most recent update being on 4/14/2022. For individuals looking for other trials, there are 32 studies actively enrolling patients with carcinoid tumors and 75 studies for Ramucirumab that still need participants."
Are there any patients who have not yet been enrolled in this trial?
"The aforementioned website indicates that this particular clinical trial is not, at present, looking for patients to participate. Although, it is worth mentioning that there are one hundred and seven other trials which are currently open to enrolment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger